Long-Acting HIV Drug Promising for Treatment-Naive Patients

(MedPage Today) -- Lenacapavir (Sunlenca) given every 26 weeks along with daily antiretroviral therapy (ART) suppressed HIV on par with conventional regimens in the first-line setting in the phase II CALIBRATE trial. Viral suppression to fewer...
Source: MedPage Today Infectious Disease - Category: Infectious Diseases Source Type: news